119 results
8-K
BLPH
Bellerophon Therapeutics, Inc.
29 Jun 23
Cost Associated with Exit or Disposal Activities
4:06pm
from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INOpulse® for the treatment of fILD. The trial did not meet its … . Overall, INOpulse® was well-tolerated with no safety concerns, consistent with what has been observed in the prior Phase 2 studies. Based
8-K
EX-99.2
31gk5bc2ux
5 Jun 23
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:08am
8-K
EX-99.1
2ze3w2d6xjpf vic
5 Jun 23
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:08am
424B5
feoswlonimic7
31 May 23
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
3b3l oeqelzxpdkui
15 May 23
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
4:54pm
8-K
ank nkjct
11 May 23
Departure of Directors or Certain Officers
5:06pm
8-K
EX-99.1
jpk79881mc v5vbwbo
11 May 23
Pivotal top-line data readout expected in mid-2023
8:30am
8-K
EX-99.1
y6vctp
31 Mar 23
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
8:29am
8-K
EX-99.1
hl3rmwt622ux
14 Nov 22
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
9:12am
8-K
EX-99.1
5qfes78ri4ovd dlsz
27 Sep 22
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:28am